← Leaderboards
Margareta Pisarska
Cedars-Sinai Medical Center
$10,063,746
Attributed
$12,045,410
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2006–24$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$12,045,410 · 5
By mechanism
R01$8,082,082 · 4
U01$3,963,328 · 1
Top collaborators
- Hsian-Rong Tseng5 shared
Most similar at Cedars-Sinai Medical Center
Same institution · by research overlap
- Edwin Melencio Posadas$4,564,053
- Neil A Bhowmick$9,206,432
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsPregnancyGenesFirst Pregnancy TrimesterFetalBaseFetusFamilyGeneticSamplingAffectPlacentationMolecularTrophoblastSurfaceMemberTranscriptional RegulationGenome-WideGenetic TranscriptionImprintGene TargetingInnovationLongevityExposure To
Grant awards (24)
The impact of sex and gender on disease progression, from developmental origins$423,609
R01 · FY2024 · AI · contact PI
Non-Invasive Prenatal Diagnostics Based on Circulating Trophoblasts$793,038
U01 · FY2023 · EB
The impact of sex and gender on disease progression, from developmental origins$139,912
R01 · FY2023 · AI · contact PI
Non-Invasive Prenatal Diagnostics Based on Circulating Trophoblasts$793,038
U01 · FY2022 · EB
The impact of sex and gender on disease progression, from developmental origins$570,535
R01 · FY2022 · AI · contact PI
Non-Invasive Prenatal Diagnostics Based on Circulating Trophoblasts$777,176
U01 · FY2021 · EB
The impact of sex and gender on disease progression, from developmental origins$570,717
R01 · FY2021 · AI · contact PI
Non-Invasive Prenatal Diagnostics Based on Circulating Trophoblasts$793,038
U01 · FY2020 · EB
The impact of sex and gender on disease progression, from developmental origins$576,562
R01 · FY2020 · AI · contact PI
Non-Invasive Prenatal Diagnostics Based on Circulating Trophoblasts$807,038
U01 · FY2019 · EB
Adverse Outcomes of Assisted Reproductive Technologies: Genetics or Epigenetics?$627,553
R01 · FY2018 · HD · contact PI
Noncoding RNA regulation of the human placental transcriptome among the sexes$449,865
R01 · FY2018 · HD · contact PI
Adverse Outcomes of Assisted Reproductive Technologies: Genetics or Epigenetics?$793,362
R01 · FY2017 · HD · contact PI
Noncoding RNA regulation of the human placental transcriptome among the sexes$449,955
R01 · FY2017 · HD · contact PI
Adverse Outcomes of Assisted Reproductive Technologies: Genetics or Epigenetics?$649,888
R01 · FY2015 · HD · contact PI
Effects of fetal sex on the first trimester transcriptome$100,000
R01 · FY2015 · HD · contact PI
Adverse Outcomes of Assisted Reproductive Technologies: Genetics or Epigenetics?$650,648
R01 · FY2014 · HD · contact PI
Adverse Outcomes of Assisted Reproductive Technologies: Genetics or Epigenetics?$618,957
R01 · FY2013 · HD · contact PI
Molecular Mechanisms of FOXL2, An Ovarian Failure Gene$248,647
R01 · FY2010 · HD · contact PI
Molecular Mechanisms of FOXL2, An Ovarian Failure Gene$162,940
R01 · FY2010 · HD · contact PI
Molecular Mechanisms of FOXL2, An Ovarian Failure Gene$251,160
R01 · FY2009 · HD · contact PI
Molecular Mechanisms of FOXL2, An Ovarian Failure Gene$251,160
R01 · FY2008 · HD · contact PI
Molecular Mechanisms of FOXL2, An Ovarian Failure Gene$253,195
R01 · FY2007 · HD · contact PI
Molecular Mechanisms of FOXL2, An Ovarian Failure Gene$293,417
R01 · FY2006 · HD · contact PI